WO2000062815A3 - Novel pharmaceutical composition suitable for gene therapy - Google Patents

Novel pharmaceutical composition suitable for gene therapy Download PDF

Info

Publication number
WO2000062815A3
WO2000062815A3 PCT/GB2000/001408 GB0001408W WO0062815A3 WO 2000062815 A3 WO2000062815 A3 WO 2000062815A3 GB 0001408 W GB0001408 W GB 0001408W WO 0062815 A3 WO0062815 A3 WO 0062815A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
gene therapy
composition suitable
novel pharmaceutical
cells
Prior art date
Application number
PCT/GB2000/001408
Other languages
French (fr)
Other versions
WO2000062815A2 (en
Inventor
Richard Charles Boucher
Martin James Ford
Larry Goldoc Johnson
Yim Man
Michael Robert West
Original Assignee
Glaxo Group Ltd
Univ North Carolina
Richard Charles Boucher
Martin James Ford
Larry Goldoc Johnson
Yim Man
Michael Robert West
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908643.1A external-priority patent/GB9908643D0/en
Priority claimed from GBGB9908636.5A external-priority patent/GB9908636D0/en
Priority claimed from GBGB9909073.0A external-priority patent/GB9909073D0/en
Priority claimed from GBGB9909297.5A external-priority patent/GB9909297D0/en
Application filed by Glaxo Group Ltd, Univ North Carolina, Richard Charles Boucher, Martin James Ford, Larry Goldoc Johnson, Yim Man, Michael Robert West filed Critical Glaxo Group Ltd
Priority to AU44170/00A priority Critical patent/AU4417000A/en
Publication of WO2000062815A2 publication Critical patent/WO2000062815A2/en
Publication of WO2000062815A3 publication Critical patent/WO2000062815A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

There is provided according to the invention a pharmaceutical composition for gene therapy on cells which comprises: (a) nucleic acid encoding a therapeutic gene and a promoter; (b) a transfection vehicle; and (c) means to disrupt the function of the junctional complex in the cells together with methods of treatment using the same.
PCT/GB2000/001408 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy WO2000062815A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44170/00A AU4417000A (en) 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9908643.1 1999-04-15
GBGB9908643.1A GB9908643D0 (en) 1999-04-15 1999-04-15 Novel pharmaceutical composition
GB9908636.5 1999-04-15
GBGB9908636.5A GB9908636D0 (en) 1999-04-15 1999-04-15 Novel pharmaceutical composition
GBGB9909073.0A GB9909073D0 (en) 1999-04-20 1999-04-20 Novel pharmaceutical composition
GB9909073.0 1999-04-20
GB9909297.5 1999-04-22
GBGB9909297.5A GB9909297D0 (en) 1999-04-22 1999-04-22 Novel pharmaceutical composition
US15375799P 1999-09-13 1999-09-13
US60/153,757 1999-09-13

Publications (2)

Publication Number Publication Date
WO2000062815A2 WO2000062815A2 (en) 2000-10-26
WO2000062815A3 true WO2000062815A3 (en) 2001-02-08

Family

ID=27517502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001408 WO2000062815A2 (en) 1999-04-15 2000-04-13 Novel pharmaceutical composition suitable for gene therapy

Country Status (2)

Country Link
AU (1) AU4417000A (en)
WO (1) WO2000062815A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092542A2 (en) * 2000-05-30 2001-12-06 Ich Productions Limited Integrin-targeting vectors having enhanced transfection activity
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Composition for the preservation of viruses
US7105347B2 (en) * 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7691580B2 (en) 2003-01-29 2010-04-06 Corning Incorporated Reverse protein delivery into cells on coded microparticles
CA2545590C (en) * 2003-11-15 2013-08-20 Polyphor Ltd. Template fixed beta-hairpin loop mimetics and their use in phage display
WO2015143254A1 (en) * 2014-03-21 2015-09-24 The Regents Of The University Of Michigan Pharmaceutical compositions comprising occludin mutants and methods of inhibiting angiogenesis therewith
CN116621966A (en) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 Therapeutic nucleic acid molecules, mixtures, medicaments and their use in the treatment of solid tumors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004745A1 (en) * 1989-09-27 1991-04-18 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
WO1997033605A1 (en) * 1996-03-15 1997-09-18 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
WO1998002452A2 (en) * 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
WO1999015649A2 (en) * 1997-09-24 1999-04-01 Elan Corporation, Plc Composition and method for enhancing paracellular transport across cell layers
CA2271826A1 (en) * 1998-11-16 2000-05-16 Douglas J. Jolly Methods and compositions for increasing the infectively of retroviruses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004745A1 (en) * 1989-09-27 1991-04-18 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
WO1997033605A1 (en) * 1996-03-15 1997-09-18 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
WO1998002452A2 (en) * 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
WO1999015649A2 (en) * 1997-09-24 1999-04-01 Elan Corporation, Plc Composition and method for enhancing paracellular transport across cell layers
CA2271826A1 (en) * 1998-11-16 2000-05-16 Douglas J. Jolly Methods and compositions for increasing the infectively of retroviruses

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOUCHER R.C.: "Status of gene therapy for cystic fibrosis lung disease.", JOURNAL OF CLINICAL INVESTIGATION, (15 FEB 1999) 103/4 (441-445)., XP002149603 *
CHU Q ET AL: "Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells.", HUMAN GENE THERAPY, vol. 10, no. 1, 1 January 1999 (1999-01-01), pages 25 - 36, XP000952585, ISSN: 1043-0342 *
HARBOTTLE R P ET AL: "An RGD -oligolysine peptide: a prototype construct for integrin -mediated gene delivery [see comments]", HUMAN GENE THERAPY,XX,XX, XP002080440, ISSN: 1043-0342 *
HART S L ET AL: "Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains.", GENE THERAPY, vol. 4, no. 11, November 1997 (1997-11-01), pages 1225 - 1230, XP000952581, ISSN: 0969-7128 *
HOCHMAN J ET AL: "MECHANISMS OF ABSORPTION ENHANCEMENT AND TIGHT JUNCTION REGULATION", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 29, 1994, pages 253 - 267, XP002054267, ISSN: 0168-3659 *
KOTZE A F ET AL: "Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2)", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 51, no. 1, 23 January 1998 (1998-01-23), pages 35 - 46, XP004108275, ISSN: 0168-3659 *
WALTERS ROBERT W ET AL: "Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 15, 9 April 1999 (1999-04-09), pages 10219 - 10226, XP002149604, ISSN: 0021-9258 *
WICKHAM T J ET AL: "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 11, no. 71, 1 November 1997 (1997-11-01), pages 8221 - 8229, XP002078898, ISSN: 0022-538X *
WONG VIVIAN ET AL: "A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier.", JOURNAL OF CELL BIOLOGY, vol. 136, no. 2, 1997, pages 399 - 409, XP002149605, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
WO2000062815A2 (en) 2000-10-26
AU4417000A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO2003040399A3 (en) Therapeutic methods for nucleic acid delivery vehicles
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
MXPA03002262A (en) Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
WO2000003683A3 (en) Liposomal encapsulated nucleic acid-complexes
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
WO1997013866A3 (en) Recombinant herpes virus vectors for expression in neuronal cells
AU682140B2 (en) Multidrug resistance gene
HUP9702377A2 (en) Self-enhancing, pharmacologically controllable expression systems
WO2002055721A3 (en) Modular transfection systems based on nucleoprotein filaments
AU8881201A (en) Tnf receptor-like molecules and uses thereof
EP0828003A3 (en) Human serine protease
WO1999033998A3 (en) Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof
AU3919997A (en) Nucleic acid constructs containing hybrid promoters for use in gene therapy
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
EP0859636A4 (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
AU2302097A (en) Spray-dried microparticles as therapeutic vehicles for use in gene therapy
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO1997023611A3 (en) Nucleic acid sequences of genes of the high mobility group proteins and uses thereof
WO1999047152A3 (en) Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1165145A4 (en) Antisense modulation of mdmx expression
AU3762699A (en) (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP